… and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen®: single-blind, randomized, crossover trial
用户tRKsRXBRKyTw
44分钟前
4
10
求助中
帖子自动结束时间: 2026-11-07 13:01:14
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性,不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
H Lubenau, P Bias, AK Maly, KE Siegler, K Mehltretter
BioDrugs, 2009
Springer
… study was conducted to compare the pharmacokinetic and pharmacodynamic characteristics
of the new biosimilar filgrastim XM02 with the marketed filgrastim (… the clinical study report …

